Phathom Pharmaceuticals Inc (PHAT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $492.63M
Last updated: Nov 17, 2026 at 11:05 AM ET
Phathom Pharmaceuticals Inc (PHAT) Stock Forecast
Analysts expect Phathom Pharmaceuticals (PHAT) to earn -$0.05 per share in the fiscal year ending Dec 31, 2026, on revenue of $315.03M. Of 12 analysts, 10 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 16.7% |
| Buy | 8 | 66.7% |
| Hold | 2 | 16.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 54.9%.
- Fiscal year ending Dec 31, 2026
- -$0.05
- EPS consensus, revenue $315.03M
- Fiscal year ending Dec 31, 2027
- $0.96
- EPS consensus, revenue $488.03M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.05 | -$0.12 to $0.02 | 5 | $315.03M | $312.90M to $318.45M | 9 |
| Dec 31, 2027 | $0.96 | $0.52 to $1.40 | 5 | $488.03M | $435.00M to $543.30M | 9 |
Quarterly Estimates
The EPS consensus rises from -$0.08 for the quarter ending Dec 31, 2026 to $0.02 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.08 | -$0.15 to $0.07 | 12 | $99.14M | $92.49M to $105.00M | 11 |
| Mar 31, 2027 | $0.02 | -$0.03 to $0.07 | 4 | $94.01M | $85.00M to $101.00M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 6 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 3 |
| Quarter ending Mar 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen from breakeven to a loss.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.05 | -$0.04 | -$0.03 | -$0.03 | $0.00 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.96 | $0.96 | $1.08 | $1.11 | $1.14 | -16.3% |
| Quarter ending Mar 31, 2027 | $0.02 | $0.01 | $0.06 | $0.06 | $0.08 | -80.9% |
Frequently Asked Questions About PHAT
What is the PHAT stock forecast?
Consensus analyst estimates put Phathom Pharmaceuticals's EPS at -$0.05 for the fiscal year ending Dec 31, 2026, on revenue of $315.03M. The consensus rating from 12 analysts is Buy.
How do analysts rate PHAT stock?
Of 12 analysts covering Phathom Pharmaceuticals, 2 rate it Strong Buy, 8 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PHAT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.05, with estimates from -$0.12 to $0.02 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.96, with estimates from $0.52 to $1.40 from 5 analysts.
What revenue do analysts expect from Phathom Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $315.03M, with estimates from $312.90M to $318.45M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $488.03M, with estimates from $435.00M to $543.30M.
How many analysts cover PHAT?
12 analysts rate Phathom Pharmaceuticals stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PHAT pages: Overview, Earnings, Forecast, Financials, Competitors